30 July 2020
Enterome initiates first clinical trial with EO2401 – an innovative microbiomeantigen based cancer immunotherapy candidate targeting aggressive brain cancer
ENTEROME SA, a clinical-stage biopharmaceutical company leveraging its unique knowledge of the microbiome-immunoinflammation axis to develop next-generation therapeutics,...